ArticleNature materials2021
Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation.
Article in Nature materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
212 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Applications of lung cancer organoids in precision medicine: from bench to bedside.Cell communication and signaling : CCS · 2023Pooled it
- Airflow controlled droplet bioprinting enables high-throughput generation of iPSC-derived thymic organoids withBiofabrication · 2026Article
- Organoids: Current Applications and Future Directions.MedComm · 2026Review
- Kidney organoids as models for hereditary kidney diseases: Toward precision medicine (Review).Experimental and therapeutic medicine · 2026Review
- Single-cell spatial mapping of human kidney development implicates the microenvironment in guiding cell fate decisions.Nature genetics · 2026Article
- Advancing Stem Cell Bioprinting to Bridge Engineered and Natural Tissue Constructs.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions.Cell proliferation · 2026Review
- Stress-relaxing granular bioprinting materials enable complex and uniform organoid self-organization.Nature materials · 2026Article
- New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026Review
- Cryopreservative Bioink Enables Direct Bioprinting of Adherent Cells.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Classification of indeterminate and off-target cell types within human kidney organoid differentiation.iScience · 2026Article
- Application of spatial transcriptomics across organoids for a high-resolution, spatial whole-transcriptome benchmarking dataset.iScience · 2026Article
- Label-free interferometry platform for drug response profiling of bioprinted tumor organoids at single-organoid resolution.Nature protocols · 2026Review
- Kidney organoid vascularization: current advancements in the field.Regenerative therapy · 2026Article
- Disease modelling with in vitro vascularised organoids.Disease models & mechanisms · 2026Review
- In vitro modeling of renal injury-induced cardiac effects using human iPSC-derived organoids.Cell communication and signaling : CCS · 2026Article
- Modeling Fabry nephropathy: insights from experimental systems towards precision nephrology.Disease models & mechanisms · 2026Review
- Developmentally inspired synthetic kidney engineering.Nature biotechnology · 2026Review
- Soft Robotics and Advanced Technologies for Minimally Invasive Bioprinting: The Future of Internal Organ Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The transcription factor Tcf21 is necessary for adoption of cell fates byAmerican journal of physiology. Renal physiology · 2026Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
Directed differentiation of human pluripotent stem cells to kidney organoids brings the prospect of drug screening, disease modelling and the generation of tissue for renal replacement. Currently, these applications are hampered by organoid variability, nephron immaturity, low throughput and limited scale. Here, we apply extrusion-based three-dimensional cellular bioprinting to deliver rapid and high-throughput generation of kidney organoids with highly reproducible cell number and viability. We demonstrate that manual organoid generation can be replaced by 6- or 96-well organoid bioprinting and evaluate the relative toxicity of aminoglycosides as a proof of concept for drug testing. In addition, three-dimensional bioprinting enables precise manipulation of biophysical properties, including organoid size, cell number and conformation, with modification of organoid conformation substantially increasing nephron yield per starting cell number. This facilitates the manufacture of uniformly patterned kidney tissue sheets with functional proximal tubular segments. Hence, automated extrusion-based bioprinting for kidney organoid production delivers improvements in throughput, quality control, scale and structure, facilitating in vitro and in vivo applications of stem cell-derived human kidney tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.